WuXi NextCODE has raised $240 million in series B, FDA slapped Celltrion with a long Form 483, Biocon's $275 million insulin plant opened shop.

Pfizer is leaning heavily on Celltrion for biosimilar development and manufacturing, but its South Korean partner has stumbled with an FDA inspection.

Biocon says it has won EMA manufacturing approval for a $275 million plant in Malaysia where it will make insulin for export to the EU.

China’s 3SBio, in a joint venture with CPE Funds, seeks to buy Canadian CDMO Therapure Biomanufacturing for $290 million pending shareholder approval.

The FDA has taken a close look at Hetero Labs' finished products plant in Telangana, India, and decided it didn't like what it found.

Samsung inked a novel drug R&D pact with Takeda, GSK China partnered with Alibaba on HPV vaccination, Gland is revising its M&A deal with Fosun.

India-based Alembic Pharmaceuticals is selling its formulation manufacturing plant in Baddi to Scott Edil Pharmacia for an undisclosed amount.

A fire disrupted production last week at an Algerian-based generics plant, according to Indian drugmaker Alembic Pharma.